Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.

"Declaration of personal interests: CR: Has served as a speaker for Pfizer. DJ: Douglas Johnson has served as a speaker for Pfizer. He is an employee of the Royal Melbourne Hospital and has no other conflicts of interest or declarations. SN has received research grants from Ferring and Abbvie and speakers honorarium from Janssen, Abbvie, Tillotts, Takeda, Olympus and Ferring. DR reports grants and personal fees from Abbvie, personal feesfrom Abgenomics, personal fees from Allergan Inc, personal feesfrom Boehringer Ingelheim Ltd, personal fees from Bristol‐MyersSquibb, personal fees from Celgene Corp/Syneos, personal feesfrom Check‐cap, personal fees from Dizal Pharmaceuticals, personalfees from GalenPharma/Atlantica, grants and personal fees fromGenentech/Roche, personal fees from Gilead Sciences, personalfees from Ichnos Sciences, personal fees from GlaxoSmithKlineGroup, grants and personal fees from Janssen Pharmaceuticals, personal fees from Lilly, personal fees from Narrow River Mgmt, personal fees from Pfizer, grants and personal fees from PrometheusLaboratories, personal fees from Reistone, grants and personal feesfrom Shire, grants and personal fees from Takeda, personal feesfrom Techlab, Inc, outside the submitted work. Professor Gibson has served as a consultant or advisory board member for Anatara, Atmo Biosciences, Immunic Therapeutics, Novozymes, Novoviah and Comvita. He has received research grants for investigator‐driven studies from Atmo Biosciences. He holds shares in Atmo Biosciences. His Department financially benefits from the sales of a digital application, booklets and online courses on the FODMAP diet. BC has received speaking fees from Abbvie, Jannsen, Pfizer, Takeda, Falk Pharmaceuticals, Chiesi and Ferring, research grants from Janssen and Ferring Pharmaceuticals and served on the advisory board of Gilead, Janssen, Celltrion, Abbvie and Novartis"

"Ralley Prentice contributed to some grammatical edits to the study. Eva Zhang is supported by a Pfizer Grant to support her fellowship. Aysha H. Al‐Ani is supported by an Australian Commonwealth Government Research grant, a Crohn’s Colitis Foundation scholarship and a University of Melbourne Scholarship. Sasha Fehily is supported by an NHMRC scholarship to support her fellowship, and has recieved Pfizer funding contribution towards a conference attendance. All authors approved the final version of the manuscript. Personal and funding interests: SF has received an education grant from Pfizer. AA is funded by scholarships from Crohn’s and Colitis Australia, Avant, the Australian Commonwealth Government and University of Melbourne and received grants from the Gastroenterological Society of Australia/Celltrion Healthcare and Janssen."